Other News To Note
Wednesday, November 16, 2011
Avraham Pharmaceuticals Ltd., of Jerusalem, raised $3 million from Yissum Research Development Co. Ltd., the technology transfer arm of the Hebrew University of Jerusalem, and other investors. The funding will be used for an ongoing Phase II trial of ladostigil in Alzheimer's disease and a planned study of the drug in mild cognitive impairment. Ladostigil is a cholinesterase and brain-selective monoamine oxidase inhibitor.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.